Powered by

Sementis and Enesi Pharma partner to develop needle-free vaccines

Nov 06, 2018 - Marketline Newswire

Australian biotechnology firm Sementis has entered into a research and development (R&D) partnership with UK-based Enesi Pharma for the development of potential vaccine candidates to treat peanut allergy and chikungunya/Zika infection.

Under the alliance, the partners will leverage Enesi Pharma’s ImplaVax needle-free implant and device technology to create and assess solid dose versions of Sementis’ peanut hypoallergy vaccine and single vectored chikungunya/Zika vaccine can...